Alumis Inc.

2 months ago · seekingalpha.com

Alumis Inc. (ALMS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

2 months ago · globenewswire.com

SOUTH SAN FRANCISCO, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company will participate in the following investor conferences:

2 months ago · seekingalpha.com

Alumis Inc. remains a late-stage biotech with no commercial product and significant risk. ALMS's value is primarily tied to envudeucitinib, a selective TYK2 inhibitor for psoriasis and lupus. The recent share price crash, driven by a lupus trial failure, is significant but may not erase envudeucitinib's potential.

2 months ago · seekingalpha.com

Alumis Inc. (ALMS) Discusses Phase IIb LUMUS Trial Results and Subgroup Insights in Type 1 Interferon-Driven Diseases Transcript

2 months ago · marketbeat.com

Alumis NASDAQ: ALMS said its Phase II LUMUS trial of envudeucitinib in systemic lupus erythematosus, or SLE, did not meet its primary or key secondary endpoints in the overall study population. However, the company said pre-specified analyses showed clinically meaningful responses among patients with a high interferon gene signature, a subgroup it plans to emphasize in future development discussions with regulators.

2 months ago · reuters.com

Alumis said on Tuesday it plans to advance its experimental drug for a type of immunity-related condition in ​a smaller subset of patients, even after the treatment failed ‌to meet the main goal of a mid-stage trial.

2 months ago · globenewswire.com

– LUMUS trial did not meet its primary and secondary endpoints in the overall trial population – – Robust responses in the prespecified subgroup of patients with high interferon gene signature (IFNGS-high) support moving forward with Phase 3 development in SLE – – Pharmacodynamic data substantiate envudeucitinib's potential in interferon-driven immune-mediated diseases – – Envudeucitinib was generally well tolerated with no new safety signals observed – – Alumis remains on track to submit an NDA for envudeucitinib in moderate-to-severe plaque psoriasis in 4Q 2026 – – Conference call and webcast scheduled for September 1 at 8:30 am EDT – SAN FRANCISCO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that its Phase 2b LUMUS trial of envudeucitinib for the treatment of moderate-to-severe systemic lupus erythematosus (SLE) did not meet its primary and secondary endpoints in the overall trial population.

3 months ago · globenewswire.com

– ONWARD3: 54% of patients reached complete skin clearance (PASI 100) at 48 weeks, positioning envudeucitinib to set a new standard in PsO –

3 months ago · zacks.com

PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs.

3 months ago · benzinga.com

Alumis Inc. (NASDAQ:ALMS) on Monday shared topline data from its ongoing ONWARD3 long-term extension study, demonstrating that its investigational oral therapy, envudeucitinib, achieved leading skin clearance rates for patients with immune-mediated diseases.